Dot Medical announced today that it received FDA investigational device exemption (IDE) approval for its access management ...
ICU patients with a central venous access device had a smaller incidence rate of device-related complications with 4% ...
The company plans to enrol a total of 140 patients in the trial of the aXess device.
Marks start of European commercial rollout of aXess™, bringing it into routine clinical practiceBuilds on CE mark approval in ...
Austin, United States, May 22, 2026 (GLOBE NEWSWIRE) -- "SNS Insider reported that global Vascular Closure Devices Market was valued at USD 1.92 billion in 2025 and is projected to reach USD 4.08 ...
A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy No significant ...
NEW YORK & MUNICH--(BUSINESS WIRE)--Venock announced today it has successfully completed the demonstration of safety and efficacy of its large bore closure system in animal studies. Venock is ...
A phase iia trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. This is an ASCO ...
ENvue Targeting Combined $10 Billion+ Enteral Feeding and Vascular Access Market Opportunity*ENvue Drive™ Demonstration Marks First Step Toward a ...
The aXess vascular access conduit. [Image from the Xeltis website]Xeltis announced today that it began European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results